D. Western Therapeutics Institute Inc risk profile
43 Elevated one input has moved against it
Measured 10 September 2026 from 6DW's filed statements. Recomputed nightly.
43 (Elevated), driven by Cash conversion at 100, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 81 | Acute | Stable | Drawdown from the 52-week high — 47.8% |
| Operating pressure | 36 | Normal | Easing | Operating-margin drift — -91.6 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.01x |
| Leverage and coverage | 35 | Normal | Stable | Interest cover — -65.13x |
| Competitive position | 26 | Normal | Easing | Revenue-growth gap against peers — -24.1 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 34Johnson & Johnson 39Abbvie Inc 58Roche Holding AG 36Merck & Co Inc 35Unitedhealth Group Inc 49Novartis AG 30Astrazeneca plc 33Thermo Fisher Scientific Inc 47AMGEN Inc 47Novo Nordisk A/S 23Abbott Laboratories 37
Financials, valuation and price history for D. Western Therapeutics Institute Inc